New drug combo may let CLL patients pause treatment
NCT ID NCT04458610
First seen Jan 13, 2026 · Last updated Apr 25, 2026 · Updated 9 times
Summary
This study tests a combination of two drugs, zanubrutinib and rituximab, in 60 adults with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if the combo can control the disease and allow patients to stop treatment for at least 6 months. Participants take both drugs by mouth or infusion, and researchers track how long they stay in remission without needing more therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.